These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33367872)

  • 1. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
    Walther CP; Winkelmayer WC; Richardson PA; Virani SS; Navaneethan SD
    Nephrol Dial Transplant; 2021 Sep; 36(10):1893-1899. PubMed ID: 33367872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study.
    Arney J; Gregg LP; Wydermyer S; Herrera MA; Richardson PA; Matheny ME; Akeroyd JM; Gobbel GT; Hung A; Virani SS; Navaneethan SD
    Cardiorenal Med; 2024; 14(1):34-44. PubMed ID: 38151011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
    Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
    J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study.
    Yang A; Shi M; Lau ESH; Wu H; Zhang X; Fan B; Kong APS; Luk AOY; Ma RCW; Chan JCN; Chow E
    EClinicalMedicine; 2023 Jan; 55():101751. PubMed ID: 36457651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
    BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
    Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
    Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Gregg LP; Richardson PA; Herrera MA; Akeroyd JM; Jafry SA; Gobbel GT; Wydermyer S; Arney J; Hung A; Matheny ME; Virani SS; Navaneethan SD
    Am J Nephrol; 2023; 54(3-4):126-135. PubMed ID: 37231800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
    Takaori K; Iwatani H; Yamato M; Ito T
    BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.